Topiramate reduces the harm of excessive drinking: Implications for public health and primary care

Addiction

Volumn 101, Issue 11, 2006, Pages 1561-1568

  Ma, Jennie Z ^a   Ait Daoud, Nassima ^b   Johnson, Bankole A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Alcohol dependence; Harm reduction; Moderate drinking; Safe drinking; Topiramate

Indexed keywords

ALCOHOL; PLACEBO; TOPIRAMATE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HARM REDUCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; ALCOHOLISM; COMMUNITY HEALTH SERVICES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSE; HARM REDUCTION; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PRIMARY HEALTH CARE; TEXAS; TIME FACTORS;

EID: 33749521898     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01576.x     Document Type: Article

References (24)

1. Johnson B. A., Ait-Daoud N., Bowden C. L., DiClemente C. C., Roache J. D., Lawson K. et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-85.
2. Johnson B. A., Ait-Daoud N., Akhtar F. Z., Ma J. Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry 2004; 61: 905-12.
3. Johnson B. A. Epidemiology of alcoholism. In: Johnson B. A., Ruiz P., Galanter M., editors. Handbook of Clinical Alcoholism Treatment . Baltimore, MD: Lippincott, Williams & Wilkins; 2003, p. 2-9.
4. US Department of Health and Human Services. 10th Special Report to the U.S. Congress on Alcohol and Health. Bethesda, MD: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism; 2000.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders , 4th edn. Washington, DC: American Psychiatric Association; 1994.
6. Babor T. F., de la Fuente J. R., Saunders J., Grant M. AUDIT: The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1992.
7. Fawcett J., Epstein P., Fiester S. J., Elkin I., Autry J. H. Clinical management - imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull 1987; 23: 309-24.
8. Imber S. D., Pilkonis P. A., Sotsky S. M., Elkin I., Watkins J. T., Collins J. F. et al. Mode-specific effects among three treatments for depression. J Consult Clin Psychol 1990; 58: 352-9.
9. Sobell L. C., Sobell M. B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J. P., editors. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods .Totowa, NJ: Humana Press Inc.; 1992, p. 41-72.
10. US Food and Drug Administration. Guidances and Information Sheets on Good Clinical Practice in FDA-Regulated Clinical Trials. Rockville, MD: US Department of Health and Human Services; 2006. Available at: http://www.fda.gov/oc/gcp/guidance.html (accessed 27 March 2006).
11. SAS Institute Inc. SAS OnlineDoc 9.1.2®. Cary, NC: SAS Institute Inc.; 2004.
12. Dawson D. A., Grant B. F., Li T. K. Quantifying the risks associated with exceeding recommended drinking limits. Alcohol Clin Exp Res 2005; 29: 902-8.
13. Sinclair J. D. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2-10.
14. Rubio G., Manzanares J., Lopez-Munoz F., Alamo C., Ponce G., Jimenez-Arriero M. A. et al. Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat 2002; 23: 361-6.
15. Kranzler H. R., Armeli S., Tennen H., Blomqvist O., Oncken C., Petry N. et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003; 23: 294-304.
16. Dufour M. C. What is moderate drinking? Defining 'drinks' and drinking levels. Alcohol Res Health 1999; 23: 5-14.
17. Gmel G., Gutjahr E., Rehm J. How stable is the risk curve between alcohol and all-cause mortality and what factors influence the shape? A precision-weighted hierarchical meta-analysis. Eur J Epidemiol 2003; 18: 631-42.
18. Dawson D. A., Grant B. F., Stinson F. S., Chou P. S., Huang B., Ruan W. J. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005; 100: 281-92.
19. Gunzerath L., Faden V., Zakhari S., Warren K. National Institute on Alcohol Abuse and Alcoholism report on moderate drinking. Alcohol Clin Exp Res 2004; 28: 829-47.
20. Goldberg D. M., Soleas G. J., Levesque M. Moderate alcohol consumption: the gentle face of Janus. Clin Biochem 1999; 32: 505-18.
21. Pearson T. A., Terry P. What to advise patients about drinking alcohol: the clinician's conundrum. JAMA 1994; 272: 967-8.
22. Marlatt G. A., Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict Behav 2002; 27: 867-86.
23. World Health Organization. The World Health Report, 2001 - Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001.
24. Gutjahr E., Gmel G., Rehm J. Relation between average alcohol consumption and disease: an overview. Eur Addict Res 2001; 7: 117-27.